

Revision date: 05-Jan-2007

Version: 2.2

Page 1 of 7

1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Pfizer Inc Pfizer Pharmaceuticals Group 235 East 42nd Street New York, New York 10017 1-212-573-2222 Pfizer Ltd Ramsgate Road Sandwich, Kent CT13 9NJ United Kingdom +00 44 (0)1304 616161

Emergency telephone number: CHEMTREC (24 hours): 1-800-424-9300 Emergency telephone number: ChemSafe (24 hours): +44 (0)208 762 8322

Material Name: Miglitol Tablets

Trade Name:	Glyset
Chemical Family:	Mixture
Intended Use:	Pharmaceutical product used as antidiabetic agent

2. COMPOSITION/INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS List	%
Miglitol	72432-03-2	276-661-6	25-100 mg***
Microcrystalline cellulose	9004-34-6	232-674-9	*
Magnesium stearate	557-04-0	209-150-3	*
Starch	9005-25-8	232-679-6	*
Titanium dioxide	13463-67-7	236-675-5	*

Ingredient	CAS Number	EU EINECS List	%
Hypromellose	9004-65-3	Not listed	*
Polysorbate 80	9005-65-6	Not listed	*
Polyethylene glycol	25322-68-3	Not listed	*

Additional Information:

* Proprietary *** per tablet/capsule/lozenge/suppository Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

3. HAZARDS IDENTIFICATION

Appearance: Signal Word:	White tablets WARNING
Statement of Hazard:	Antidiabetic drug: has blood-sugar lowering properties Possible risk of harm to the unborn child
Additional Hazard Information:	
Short Term:	Not an eye irritant, Not a skin irritant, Not acutely toxic (based on components).
Long Term:	Animal studies have shown a potential to cause adverse effects on the fetus.
Known Clinical Effects:	The most common adverse effects reported with clinical use were diarrhea, nausea, rash, and vomiting.
EU Indication of danger:	Toxic to Reproduction; Category 3

Material Name: Miglitol Tablets Revision date: 05-Jan-2007

EU Hazard Symbols:



EU Risk Phrases:	R63 - Possible risk of harm to the unborn child.	
Note:	This document has been prepared in accordance with stand require the inclusion of all known hazards of the active subs regardless of the potential risk. The precautionary statement	

This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

4. FIRST AID MEASURES

Eye Contact:	Immediately flush eyes with water for at least 15 minutes. If irritation occurs or persists, get medical attention.
Skin Contact:	Remove clothing and wash affected skin with soap and water. This material may not be completely removed by conventional laundering. Consult professional laundry service. Do not home launder. If irritation occurs or persists, get medical attention.
Ingestion:	Get medical attention. Do not induce vomiting unless directed by medical personnel. Never give anything by mouth to an unconscious person.
Inhalation:	Remove to fresh air. If not breathing, give artificial respiration. Get medical attention.

5. FIRE FIGHTING MEASURES

Extinguishing Media:	Use carbon dioxide, dry chemical, or water spray.
Hazardous Combustion Products:	Formation of toxic gases is possible during heating or fire.
Fire Fighting Procedures:	During all fire fighting activities, wear appropriate protective equipment, including self- contained breathing apparatus.
Fire / Explosion Hazards:	Not applicable

6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions:	Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.
Measures for Cleaning / Collecting:	Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.
Measures for Environmental Protections:	Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.
Additional Consideration for Large Spills:	Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

General Handling:	If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. Minimize dust generation and accumulation. Use with adequate ventilation.	
Storage Conditions:	Store at room temperature in properly labeled containers. Keep away from heat, sparks and flames.	

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Microcrystalline cellulose		
OSHA - Final PELS - TWAs:	= 15 mg/m³ TWA = 5 mg/m³ TWA	total
ACGIH Threshold Limit Value (TWA) Australia TWA	= 10 mg/m ³ TWA = 10 mg/m ³ TWA	
Magnesium stearate		
ACGIH Threshold Limit Value (TWA) Australia TWA	= 10 mg/m ³ TWA = 10 mg/m ³ TWA	except stearates of toxic metals
Starch		
OSHA - Final PELS - TWAs:	= 15 mg/m³ TWA = 5 mg/m³ TWA	total
ACGIH Threshold Limit Value (TWA) Australia TWA	= 10 mg/m ³ TWA = 10 mg/m ³ TWA	
Titanium dioxide		
OSHA - Final PELS - TWAs: ACGIH Threshold Limit Value (TWA) Australia TWA	= 15 mg/m³ TWA = 10 mg/m³ TWA = 10 mg/m³ TWA	total

The exposure limit(s) listed for solid components are only relevant if dust may be generated.

Engineering Controls:

Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes.

Personal Protective Equipment:

Hands:	Not required for the normal use of this product. Wear protective gloves when working with large quantities.
Eyes:	Not required under normal conditions of use. Wear safety glasses or goggles if eye contact is possible.
Skin:	Not required for the normal use of this product. Wear protective clothing when working with large quantities.
Respiratory protection:	Not required for the normal use of this product. Whenever excessive air contamination (dust, mist, vapor) is generated, respiratory protection, with appropriate protection factors, should be used to minimize exposure.

9. PHYSICAL AND CHEMICAL PROPERTIES:

Physical State:	Tablets	Color:	White
Molecular Formula:	Mixture	Molecular Weight:	Mixture

10. STABILITY AND REACTIVITY

Stability: Conditions to Avoid: Incompatible Materials:

General Information:

Stable under normal conditions of use. None known As a precautionary measure, keep away from strong oxidizers.

11. TOXICOLOGICAL INFORMATION

There are no data for this formulation. The remaining information describes the potential hazards of the individual ingredients.

Acute Toxicity: (Species, Route, End Point, Dose)

Miglitol

Rat Oral LD50 > 10,000 mg/kg Dog Oral LD50 > 10,000 mg/kg

Starch

Mouse IP LD50 6600 mg/kg

Microcrystalline cellulose

Rat Oral LD50 > 5000 mg/kg Rabbit Dermal LD50 > 2000 mg/kg

Magnesium stearate

Rat Oral LD50 > 2000 mg/kg Rat Inhalation LC50 > 2000 mg/m³

Hypromellose

Rat Oral LD50 > 10,000 mg/kg

Titanium dioxide

Rat Oral LD50 > 7500 mg/kg Rat Subcutaneous LD 50 50 mg/kg

Polysorbate 80

Rat Oral LD50 25 g/kg Acute Toxicity Comments:

A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Miglitol

Eye Irritation Non-irritating Skin Irritation Non-irritating

Microcrystalline cellulose

Skin IrritationRabbitNon-irritatingEye IrritationRabbitNon-irritating

Polyethylene glycol

Eye Irritation Rabbit Mild Skin Irritation Rabbit Mild

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Miglitol

Reproductive & Fertility Rat Oral 300 mg/kg NOAEL Fertility Embryo / Fetal Development Rat Oral 450 mg/kg NOAEL Not Teratogenic Embryo / Fetal Development NOAEL Not Teratogenic Rabbit Oral 200 mg/kg Embryo / Fetal Development Rabbit Oral 200 mg/kg LOAEL Fetotoxicity Peri-/Postnatal Development Rat Oral 300 mg/kg LOAEL Fetotoxicity

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Miglitol

Bacterial Mutagenicity (Ames)Salmonella , E. coliNegativeIn Vivo MicronucleusMouseNegativeMammalian Cell MutagenicityChinese Hamster Ovary (CHO) cellsNegative

See below

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Miglitol

21 Month(s) Mouse Oral 500 mg/kg NOAEL Not carcinogenic 2 Year(s) Rat Oral 500 mg/kg NOAEL Not carcinogenic

Carcinogen Status:

Titanium dioxide	
IARC:	Group 2B
OSHA:	Present

12. ECOLOGICAL INFORMATION

Environmental Overview:

Environmental properties have not been thoroughly investigated. Releases to the environment should be avoided.

13. DISPOSAL CONSIDERATIONS

Disposal Procedures:

Dispose of waste in accordance with all applicable laws and regulations.

14. TRANSPORT INFORMATION

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

EU Symbol: EU Indication of danger: Xn Toxic to Reproduction; Category 3

EU Risk Phrases:

Material Name: Miglitol Tablets Revision date: 05-Jan-2007

Page 6 of 7 Version: 2.2

R63 - Possible risk of harm to the unborn child.

EU Safety Phrases:

S22 - Do not breathe dust.

S36/37 - Wear suitable protective clothing and gloves.

S53 - Avoid exposure - obtain special instructions before use.

OSHA Label: WARNING Antidiabetic drug: has blood-sugar lowering properties Possible risk of harm to the unborn child

Canada - WHMIS: Classifications

WHMIS hazard class: D2a very toxic materials



Miglitol Standard for the Uniform Scheduling for Drugs and Poisons: EU EINECS List	Schedule 4 276-661-6	
Microcrystalline cellulose Inventory - United States TSCA - Sect. 8(b) Australia (AICS): EU EINECS List	XU Present 232-674-9	
Magnesium stearate Inventory - United States TSCA - Sect. 8(b) Australia (AICS): EU EINECS List	Present Present 209-150-3	
Hypromellose Inventory - United States TSCA - Sect. 8(b) Australia (AICS): Standard for the Uniform Scheduling for Drugs and Poisons:	XU Present Schedule 4	
Starch Inventory - United States TSCA - Sect. 8(b) Australia (AICS): EU EINECS List	XU Present 232-679-6	
Titanium dioxide Inventory - United States TSCA - Sect. 8(b) Australia (AICS): EU EINECS List	Present Present 236-675-5	
Polysorbate 80		

Inventory - United States Australia (AICS):	s TSCA - Sect. 8(b)	XU Present
Polyethylene glycol Inventory - United States	s TSCA - Sect. 8(b)	XU
Australia (AICS):		Present
16. OTHER INFORMATIO	N	
Reasons for Revision:	Updated Section 3 - Hazard Identification. Updated Section 5 - Fire Fighting Measures. Updated Section 6 - Accidental Release Measures. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 11 - Toxicology Information. Updated Section 13 - Disposal Considerations.	
Prepared by:	Toxicology and Hazard Communication	

Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied.

End of Safety Data Sheet